Article thumbnail

Huntington's Disease: An Immune Perspective

By Annapurna Nayak, Rafia Ansar, Sunil K. Verma, Domenico Marco Bonifati and Uday Kishore


Huntington's disease (HD) is a progressive neurodegenerative disorder that is caused by abnormal expansion of CAG trinucleotide repeats. Neuroinflammation is a typical feature of most neurodegenerative diseases that leads to an array of pathological changes within the affected areas in the brain. The neurodegeneration in HD is also caused by aberrant immune response in the presence of aggregated mutant huntingtin protein. The effects of immune activation in HD nervous system are a relatively unexplored area of research. This paper summarises immunological features associated with development and progression of HD

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease,”
  2. (2006). a v e s e ,A .G e r h a r d ,Y .F .T a ie ta l . ,“ M i c r o g l i a la c t i v a t i o n correlates with severity in Huntington disease: a clinical and PET study,”
  3. (2007). A.Dalrymple,E.J.Wild,R.Joubertetal.,“Proteomicprofiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates,”
  4. (1986). Activation of complement by myelin: identification of C1-binding proteins of human myelin from central nervous tissue,”
  5. (2002). Aggregateprone proteins with polyglutamine and polyalanine expansions are degraded by autophagy,”
  6. (2007). Aggregation of expanded huntingtin in the brains of patients with Huntington disease,”
  7. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain,”
  8. (2010). Association of plasma clusterin concentration with severity, pathology, and progressioninAlzheimer disease,”
  9. (2000). C1q: structure, function, and receptors,”
  10. (2010). Cargo recognition failure is responsible for inefficient autophagy
  11. (2000). Complement component C1q modulates the phagocytosis of Aβ by microglia,”
  12. (2009). Does neuroinflammation fan the flame in neurodegenerative diseases?”
  13. (1998). Du,K.R.Bales,R.C.Dodeletal.,“α2-macroglobulinattenuates β-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons,”
  14. (2001). Early and progressive accumulation of reactive microglia in the Huntington disease brain,”
  15. (2010). Early synaptic pathophysiology in neurodegeneration: insights from Huntington’s disease,”
  16. (2010). Excitotoxicity of TNFα derived from KA activated microglia on hippocampal neurons in vitro and in vivo,”
  17. (2005). Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity,”
  18. (2001). Glutamate transporters in neurologic disease,”
  19. (2000). Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy,”
  20. (2008). Huntington’s disease: degradation of mutant huntingtin by autophagy,”
  21. (1994). Huntington’s disease: pathogenesis, diagnosis and treatment,”
  22. (2007). Imaging microglial activation in Huntington’s disease,”
  23. (1995). Inactivation of the mouse Huntington’s disease gene homolog
  24. (1999). Increased complement biosynthesis by microglia and complement activation on neurons
  25. (2005). Involvement of proinflammatory factors, apoptosis,
  26. (2002). Lessons from animal models of Huntington’s disease,”
  27. (2005). Microglia in health and disease,”
  28. (2007). Microglial activation in presymptomatic Huntington’s disease gene carriers,”
  29. (2010). Mutant huntingtin in glial cells exacerbates neurological symptoms of huntington disease mice,”
  30. (2008). N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking,”
  31. (2001). Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice,”
  32. (1985). Neuropathological classification of Huntington’s disease,”
  33. On Chorea,” Medical and Surgical Reporter
  34. (1997). P e n n e yJ r . ,J .P .V o n s a t t e l ,M .E .M a c D o n a l d
  35. (2005). Raaijmakers et al., “Structures of complement component C3 provide insightsNeurology
  36. (2007). Role of complement in neurodegeneration and neuroinflammation,”
  37. (2004). S t r e i t ,R .E .M r a k ,a n dW .S .T .G r i ffin, “Microglia and neuroinflammation: a pathological perspective,”
  38. (2002). Structural biology of the C1 complex of complement unveils the mechanisms of its activation and proteolytic activity,”
  39. (2006). The complement system in central nervous system diseases,”
  40. (1997). Therapeutic strategies for Huntington’s disease based on a molecular understanding of the disorder,”
  41. (1999). Turmaine et al., “Formation of polyglutamine inclusions in non-CNS tissue,”
  42. (1999). Vacuolar import of proteins and organelles from the cytoplasm,”
  43. (2002). Visualising microglial activation in vivo,”
  44. (2003). Wildtype huntingtin plays a role in brain development and neuronalsurvival,”MolecularNeurobiology,vol.28,no.3,pp.259– 275,